Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies.

@article{Garrett2005PhaseIS,
  title={Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies.},
  author={Christopher R. Garrett and Mayer N. Fishman and Randall R Rago and Charles C. Williams and Anne M Dellaportas and J Joseph Mahany and Richard M. Lush and William S Dalton and Ashwin Gollerkeri and Marvin B. Cohen and Daniel Sullivan},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2005},
  volume={11 9},
  pages={3335-41}
}
PURPOSE Preclinical studies show that BMS-188797 has a broad spectrum of antitumor activity in in vitro cytotoxicity assays and tumor xenograft models. We did a phase I trial designed to determine the maximum tolerated dose and the pharmacokinetics of BMS-188797 when administered i.v. MATERIALS AND METHODS BMS-188797 was administered i.v. over 60 minutes once every 21 days to 51 patients. The initial dose cohort of 3.75 mg/m(2) was set at approximately one third the lethal dose in dogs. Doses… CONTINUE READING